Enpatoran low dose

DRUG2 trials

Sponsors

EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions

HealthySystemic Lupus Erythematosus

Phase 1

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

CompletedNCT06589726

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyHealthy

Start: 2024-09-10End: 2024-12-02Updated: 2024-12-19

Phase 2

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

CompletedNCT05162586

EMD Serono Research & Development Institute, Inc.Systemic Lupus Erythematosus

Start: 2022-03-31End: 2024-11-20Updated: 2025-12-01

Related Papers

RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF ENPATORAN, A SMALL MOLECULE TOLL-LIKE RECEPTOR 7/8 INHIBITOR, IN CUTANEOUS LUPUS ERYTHEMATOSUS: RESULTS FROM COHORT A

The Journal of Rheumatology2025-05-209 citations

P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE/CLE)

Poster presentations2024-03-01

Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

Clinical Pharmacology & Therapeutics2024-02-2816 citations

LP-183 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)

2023-07-01

1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW)

2022-12-01

PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)

2022-09-27